Selected article for: "absolute lymphocyte and lymphocyte count"
Author: Marty, Francisco M; Chemaly, Roy F; Mullane, Kathleen M; Lee, Dong-Gun; Hirsch, Hans H; Small, Catherine B; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R; Chien, Jason W; Dadwal, Sanjeet S
Title: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
  • Document date: 2019_12_3
    • ID: sl45z4i0_26
    Snippet: Primary and secondary efficacy endpoints did not differ appreciably between patients treated with presatovir relative to placebo in subgroups defined by absolute lymphocyte count on day 1, presence of GVHD, time from onset of RSV symptoms to study treatment, and timing of RSV infection after HCT (Supplemental Tables 6-9 ). Optional extended viral monitoring and serologic responses to RSV infection are presented in the Supplemental Results......
    Document: Primary and secondary efficacy endpoints did not differ appreciably between patients treated with presatovir relative to placebo in subgroups defined by absolute lymphocyte count on day 1, presence of GVHD, time from onset of RSV symptoms to study treatment, and timing of RSV infection after HCT (Supplemental Tables 6-9 ). Optional extended viral monitoring and serologic responses to RSV infection are presented in the Supplemental Results.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and RSV infection: 1, 2
    • absolute lymphocyte count and treatment study: 1, 2, 3
    • GVHD presence and treatment study: 1
    • lymphocyte count and RSV infection: 1, 2, 3, 4, 5, 6, 7
    • lymphocyte count and secondary primary efficacy: 1
    • lymphocyte count and serologic response: 1
    • lymphocyte count and treatment study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • lymphocyte count and viral monitoring: 1
    • RSV infection and secondary primary efficacy: 1
    • RSV infection and treatment study: 1, 2, 3, 4, 5, 6
    • RSV infection and viral monitoring: 1
    • secondary primary efficacy and treatment study: 1, 2, 3, 4, 5
    • secondary primary efficacy endpoint and treatment study: 1, 2
    • serologic response and viral monitoring: 1